A critical appraisal of the effectiveness of UK perennial energy crops policy since 1990

Energy crops are cultivated primarily for bioenergy production, but can also have wider benefits to agriculture and the environment. Policies put in place in the UK and Europe have promoted bioenergy and the growth of energy crops. Despite the various policy support mechanisms the cultivation of perennial energy crops has proceeded at a low rate. This study rigorously analyses some of the key UK bioenergy policies since 1990 to assess why perennial energy crops have not fulfilled their potential. The UK energy crops market is scrutinised and shows the industry is still nascent compared to Government aspirations. Case studies of both successful and unsuccessful projects are evaluated to reveal how effective different policies have been in establishing UK perennial energy crops. This original review shows significantly that none of the projects, initiatives or schemes described can be viewed as an absolute success. The main obstacles that have hindered progress include: the lack of long term supportive energy crops policy, the failure of headline projects and organisations, the lack of competitiveness of long term perennial crop options compared to annual crops, bureaucracy of schemes, over-ambitious projects, and large-scale support schemes tending to favour imported biomass rather than support domestic supply.25 years of failed energy crops policy suggests there needs to be a long term strategy. Future support for the sector must join up policy between different Government departments to recognise multi-functional benefits of perennial energy crops. Support mechanisms could aim to provide a competitive advantage for local supply and use, and improve management of cashflows during establishment. The risk burden should be shared between suppliers and end-users. Smaller-scale projects using established technologies are required with energy crops introduced in a phased manner. Supply-side measures need to be balanced with demand-side incentives to link supply with end-user markets

Strengthening the development of the short-rotation plantations bioenergy sector: Policy insights from six European countries

This paper, based on a participatory methodological framework involving expert stakeholders and researchers from six European countries (Germany, Ireland, Poland, Spain, Sweden and UK), analyses the priority issues for the development of short-rotation plantations (SRP), and proposes a series of policy strategies to strengthen this development. The results indicate that there is a lack of awareness of the multifaceted benefits of SRP at the level of farmers, policy makers and public authorities. More research is required to put a value on the multifunctionality of SRP and justify its public support. Small-scale projects using established technologies are also required with energy crops introduced in a phased manner. The simultaneous dissemination of this knowledge upwards to policy makers and downwards to producers and farmers is critical in the success of SRP. Also, greater financial support on both the supply and demand side is highlighted as being necessary: on the supply side linking multifunctional benefits of SRP and targeted payments, along with increased long-term contractual arrangements between farmers and energy plant operators; demand side incentives should overcome any difference in price between fossil fuels and energy crops. Groups to lobby for the uptake and support of SRP and bioenergy are also of necessary

A review of Willow (Salix spp.) as an integrated biorefinery feedstock

Publication history: Accepted - 13 October 2022; Published online - 22 October 2022Throughout history, the genus Salix (willow) has been an incredibly useful temperate plant for humans, with widespread global distribution and species indigenous to all continents except Antarctica. Estimations of the number of species range from 450 to 520 worldwide, and there are still more natural hybrids and multi-hybrid combinations. Several biomass willow breeding programmes have been established across the globe. All of these attempt to produce fast-growing, high-yielding stems with a straight habit and minimal side branching that are highly adaptable to different sites and are also disease and pest resistant. Short rotation coppice (SRC) cultivation involves growing willow at close spacings with a stocking rate of around 15,000 per hectare with harvests every 2–4 years. The crop is mechanically harvested, typically using a forager, and material has recently been used for bioenergy applications. Trial plots have achieved yields of up to 20 odt/ha/yr, whilst well-tended commercial crops have yielded up to 14 odt/ha/yr. Global willow breeding programmes have produced a wide variety of commercial genotypes that have suitable properties for easy planting and harvesting and have the added benefit of elevated levels of bioactive compounds, including salicin, present in the bark, which can be used in medical and veterinary applications. These high-yielding willow varieties grow well in the wetter regions of the globe, including NW Europe, and afford multiple harvests before re-planting. Salix's versatility and adaptability and the SRC cultivation process make them an ideal candidate feedstock for use in an integrated biorefinery to produce a range of biobased materials, including pharmaceuticals, and biocomposites, fuels, energy and fertiliser.The authors would like to thank the European Union's Interreg North West Europe programme, financed by the European Regional Development Fund (Biowill; project number 964) and also the Welsh Government (Environmental Evidence Programme) for support and to Micaela Cosgrove (European Landowners Organisation) for final proof reading

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19. In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978. Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50–72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74–1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67–1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74–1·58]; BRII-196 plus BRII-198 1·00 [0·68–1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91–1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88–1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90. Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19. US National Institutes of Health and Operation Warp Spee